Eli Lilly's Ken Custer said the obesity market is in its infancy despite millions of patients on these medicines. He noted billions could potentially benefit from the treatments. The scale of what remains to be accomplished surprised him most about the category's development.
Tap to vote and see what everyone thinks.
Summary by ByteBrief
Trump bull market may end but Eli Lilly and another stock will outperform